Short answer
Humacyte, Inc. (HUMA) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1M (up 36.5% year over year) with net income of −$16M.
Q3 2026 key financials · XBRL
- Revenue
- $1M
- +36.5% YoY · +153.2% QoQ
- Net income
- −$16M
- +11.3% YoY · +57.8% QoQ
- Operating margin
- -2287.8%
- EPS (diluted)
- −$0.05
- +58.3% YoY · +68.8% QoQ
Source: XBRL data from the Humacyte, Inc. (HUMA) Q3 2026 10-Q on SEC EDGAR. USD.
Humacyte, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $1.0M, up from $0.8M YoY, driven by Symvess product sales
- Operating loss $23.5M vs $24.4M YoY, operating margin -2,288.3% vs -3,048.8%
- Symvess product revenue $1.0M vs $0.7M, the only reported product line
- Cash, equivalents and restricted cash $64.9M, up from $19.8M; operating cash use $62.1M vs $78.9M
- Going-concern risk, insufficient liquidity beyond one year without higher Symvess sales or additional capital
Risk Factors
- Cost-saving execution risk: May 2026 workforce reduction of approximately 45 employees
- Nasdaq compliance risk: $1.00 bid-price requirement, with compliance deadline January 27, 2027
- Delisting financing risk: Nasdaq removal could impair liquidity and capital-raising ability
- Workforce disruption risk: severance costs could negatively impact cash flows
- Talent retention risk: unplanned attrition could reduce productivity and organizational knowledge
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Humacyte, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.